These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 30642444)

  • 1. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
    Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing a histology-specific biologically effective dose threshold for lung stereotactic ablative radiotherapy (SABR): Is ≥100 Gy
    Abel S; Hasan S; Verma V; Weksler B; Colonias A; Horne ZD; Wegner RE
    Lung Cancer; 2019 Sep; 135():169-174. PubMed ID: 31446991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Baine MJ; Verma V; Schonewolf CA; Lin C; Simone CB
    Lung Cancer; 2018 Apr; 118():20-26. PubMed ID: 29571997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.
    Liu F; Farris MK; Ververs JD; Hughes RT; Munley MT
    Radiother Oncol; 2024 Jun; 195():110257. PubMed ID: 38548113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse.
    Loganadane G; Martinetti F; Mercier O; Krhili S; Riet FG; Mbagui R; To H; Le Péchoux C; Levy A
    Cancer Treat Rev; 2016 Nov; 50():240-246. PubMed ID: 27768919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
    Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy.
    Hörner-Rieber J; Bernhardt D; Dern J; König L; Adeberg S; Paul A; Heussel CP; Kappes J; Hoffmann H; Herth FJP; Debus J; Warth A; Rieken S
    Radiother Oncol; 2017 Nov; 125(2):317-324. PubMed ID: 28919006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
    Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
    Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
    Phillips I; Sandhu S; Lüchtenborg M; Harden S
    Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
    Haque W; Verma V; Polamraju P; Farach A; Butler EB; Teh BS
    Radiother Oncol; 2018 Nov; 129(2):264-269. PubMed ID: 30031630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
    Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
    JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer.
    Holgersson G; Bergström S; Bergqvist M; Nyman J; Hoye E; Helsing M; Friesland S; Holgersson M; Birath E; Ekman S; Blystad T; Ewers SB; Mörth C; Löden B; Henriksson R
    Eur J Cancer; 2011 Nov; 47(16):2415-21. PubMed ID: 21726999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
    de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
    Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
    Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.
    Harris JP; Nwachukwu C; Qian Y; Pollom E; Loo BW; Das M; Diehn M
    Lung Cancer; 2018 Oct; 124():76-85. PubMed ID: 30268484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.
    Ager BJ; Wells SM; Gruhl JD; Stoddard GJ; Tao R; Kokeny KE; Hitchcock YJ
    Lung Cancer; 2019 Dec; 138():6-12. PubMed ID: 31593894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
    Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
    Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.